JP2007526460A - 細胞集団のタンパク質発現プロファイルの作成のための分析用プラットフォームおよび方法 - Google Patents
細胞集団のタンパク質発現プロファイルの作成のための分析用プラットフォームおよび方法 Download PDFInfo
- Publication number
- JP2007526460A JP2007526460A JP2007501122A JP2007501122A JP2007526460A JP 2007526460 A JP2007526460 A JP 2007526460A JP 2007501122 A JP2007501122 A JP 2007501122A JP 2007501122 A JP2007501122 A JP 2007501122A JP 2007526460 A JP2007526460 A JP 2007526460A
- Authority
- JP
- Japan
- Prior art keywords
- solid support
- different
- lysate
- proteins
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 211
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 211
- 238000000034 method Methods 0.000 title claims abstract description 124
- 238000005259 measurement Methods 0.000 claims abstract description 216
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 154
- 239000006166 lysate Substances 0.000 claims abstract description 140
- 238000001514 detection method Methods 0.000 claims abstract description 127
- 239000007787 solid Substances 0.000 claims abstract description 115
- 238000009739 binding Methods 0.000 claims abstract description 94
- 230000027455 binding Effects 0.000 claims abstract description 93
- 230000001737 promoting effect Effects 0.000 claims abstract description 51
- 239000013592 cell lysate Substances 0.000 claims abstract description 45
- 238000003491 array Methods 0.000 claims abstract description 41
- 230000009870 specific binding Effects 0.000 claims abstract description 33
- 238000000151 deposition Methods 0.000 claims abstract description 24
- 238000004458 analytical method Methods 0.000 claims abstract description 16
- 230000019491 signal transduction Effects 0.000 claims abstract description 11
- 238000012216 screening Methods 0.000 claims abstract description 8
- 239000010410 layer Substances 0.000 claims description 141
- 210000004027 cell Anatomy 0.000 claims description 132
- 239000000523 sample Substances 0.000 claims description 104
- 150000001875 compounds Chemical class 0.000 claims description 62
- 210000001519 tissue Anatomy 0.000 claims description 51
- 239000012491 analyte Substances 0.000 claims description 46
- 230000003287 optical effect Effects 0.000 claims description 37
- 230000008859 change Effects 0.000 claims description 27
- 239000000463 material Substances 0.000 claims description 25
- 230000005284 excitation Effects 0.000 claims description 20
- 238000010790 dilution Methods 0.000 claims description 18
- 239000012895 dilution Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 229910052751 metal Inorganic materials 0.000 claims description 17
- 239000002184 metal Substances 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 15
- 239000003550 marker Substances 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 230000008021 deposition Effects 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 10
- 239000005090 green fluorescent protein Substances 0.000 claims description 10
- 238000004020 luminiscence type Methods 0.000 claims description 10
- -1 lymph fluid Substances 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 239000012788 optical film Substances 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 9
- 230000026731 phosphorylation Effects 0.000 claims description 9
- 238000006366 phosphorylation reaction Methods 0.000 claims description 9
- 210000001124 body fluid Anatomy 0.000 claims description 8
- 239000010839 body fluid Substances 0.000 claims description 8
- 230000013595 glycosylation Effects 0.000 claims description 8
- 238000006206 glycosylation reaction Methods 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 238000007069 methylation reaction Methods 0.000 claims description 8
- 230000001086 cytosolic effect Effects 0.000 claims description 7
- 239000011521 glass Substances 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 6
- 229910044991 metal oxide Inorganic materials 0.000 claims description 6
- 230000011987 methylation Effects 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- 230000009871 nonspecific binding Effects 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 150000003573 thiols Chemical class 0.000 claims description 6
- 239000013594 undilute cell lysate Substances 0.000 claims description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052737 gold Inorganic materials 0.000 claims description 5
- 239000010931 gold Substances 0.000 claims description 5
- 150000004706 metal oxides Chemical class 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000000700 radioactive tracer Substances 0.000 claims description 5
- 229910052709 silver Inorganic materials 0.000 claims description 5
- 239000004332 silver Substances 0.000 claims description 5
- 239000002356 single layer Substances 0.000 claims description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 5
- 108010052285 Membrane Proteins Proteins 0.000 claims description 4
- 108091000080 Phosphotransferase Proteins 0.000 claims description 4
- 108010026552 Proteome Proteins 0.000 claims description 4
- 239000012790 adhesive layer Substances 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 239000000919 ceramic Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 150000002118 epoxides Chemical class 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- 108091006047 fluorescent proteins Proteins 0.000 claims description 4
- 102000034287 fluorescent proteins Human genes 0.000 claims description 4
- 210000004209 hair Anatomy 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 108091005573 modified proteins Proteins 0.000 claims description 4
- 102000035118 modified proteins Human genes 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 102000020233 phosphotransferase Human genes 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 239000004033 plastic Substances 0.000 claims description 4
- 229920003023 plastic Polymers 0.000 claims description 4
- 229920006112 polar polymer Polymers 0.000 claims description 4
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 4
- 102000035123 post-translationally modified proteins Human genes 0.000 claims description 4
- 108091005626 post-translationally modified proteins Proteins 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 4
- 239000010453 quartz Substances 0.000 claims description 4
- 238000011160 research Methods 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 210000001179 synovial fluid Anatomy 0.000 claims description 4
- 210000001138 tear Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 108010089610 Nuclear Proteins Proteins 0.000 claims description 3
- 125000005600 alkyl phosphonate group Chemical group 0.000 claims description 3
- 238000003795 desorption Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000005194 fractionation Methods 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000005286 illumination Methods 0.000 claims description 2
- 238000000813 microcontact printing Methods 0.000 claims description 2
- 238000000206 photolithography Methods 0.000 claims description 2
- 238000012910 preclinical development Methods 0.000 claims description 2
- 230000019639 protein methylation Effects 0.000 claims description 2
- 230000009822 protein phosphorylation Effects 0.000 claims description 2
- 238000004451 qualitative analysis Methods 0.000 claims description 2
- 238000004445 quantitative analysis Methods 0.000 claims description 2
- 230000008844 regulatory mechanism Effects 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims 4
- 229910000077 silane Inorganic materials 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 210000004880 lymph fluid Anatomy 0.000 claims 2
- 239000012780 transparent material Substances 0.000 claims 2
- 239000000470 constituent Substances 0.000 claims 1
- 238000009509 drug development Methods 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000002331 protein detection Methods 0.000 claims 1
- 150000004760 silicates Chemical class 0.000 claims 1
- 238000013517 stratification Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 120
- 230000000875 corresponding effect Effects 0.000 description 27
- 238000003556 assay Methods 0.000 description 18
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 17
- 229940098773 bovine serum albumin Drugs 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 16
- 206010009944 Colon cancer Diseases 0.000 description 14
- 230000004913 activation Effects 0.000 description 13
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 11
- 102000007469 Actins Human genes 0.000 description 10
- 108010085238 Actins Proteins 0.000 description 10
- 208000029742 colonic neoplasm Diseases 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 230000037361 pathway Effects 0.000 description 8
- 239000012114 Alexa Fluor 647 Substances 0.000 description 7
- 238000003374 lysate array Methods 0.000 description 7
- 238000000691 measurement method Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 238000006073 displacement reaction Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000021736 acetylation Effects 0.000 description 5
- 238000006640 acetylation reaction Methods 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 229920001222 biopolymer Polymers 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 239000003068 molecular probe Substances 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000004756 silanes Chemical class 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- BPUBBGLMJRNUCC-UHFFFAOYSA-N oxygen(2-);tantalum(5+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Ta+5].[Ta+5] BPUBBGLMJRNUCC-UHFFFAOYSA-N 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- PBCFLUZVCVVTBY-UHFFFAOYSA-N tantalum pentoxide Inorganic materials O=[Ta](=O)O[Ta](=O)=O PBCFLUZVCVVTBY-UHFFFAOYSA-N 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 238000004435 EPR spectroscopy Methods 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- TVACALAUIQMRDF-UHFFFAOYSA-N dodecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCOP(O)(O)=O TVACALAUIQMRDF-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000000524 functional group Chemical class 0.000 description 2
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 108091008147 housekeeping proteins Proteins 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000003730 Alpha-catenin Human genes 0.000 description 1
- 108090000020 Alpha-catenin Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 108091005948 blue fluorescent proteins Proteins 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000000370 laser capture micro-dissection Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- ORUIBWPALBXDOA-UHFFFAOYSA-L magnesium fluoride Chemical compound [F-].[F-].[Mg+2] ORUIBWPALBXDOA-UHFFFAOYSA-L 0.000 description 1
- 229910001635 magnesium fluoride Inorganic materials 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical class O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2004/002127 WO2005095965A1 (en) | 2004-03-03 | 2004-03-03 | Analytical platform and method for generating protein expression profiles of cell populations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007526460A true JP2007526460A (ja) | 2007-09-13 |
| JP2007526460A5 JP2007526460A5 (enExample) | 2011-02-24 |
Family
ID=34957113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007501122A Pending JP2007526460A (ja) | 2004-03-03 | 2004-03-03 | 細胞集団のタンパク質発現プロファイルの作成のための分析用プラットフォームおよび方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080020409A1 (enExample) |
| EP (1) | EP1730530A1 (enExample) |
| JP (1) | JP2007526460A (enExample) |
| CN (1) | CN1954213A (enExample) |
| AU (1) | AU2004318038A1 (enExample) |
| CA (1) | CA2559803A1 (enExample) |
| WO (1) | WO2005095965A1 (enExample) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014516644A (ja) * | 2011-04-29 | 2014-07-17 | セブンス センス バイオシステムズ，インコーポレーテッド | 血斑または他の体液の収集および／または操作のためのデバイスおよび方法 |
| US9730624B2 (en) | 2009-03-02 | 2017-08-15 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving fluids |
| US9775551B2 (en) | 2009-03-02 | 2017-10-03 | Seventh Sense Biosystems, Inc. | Devices and techniques associated with diagnostics, therapies, and other applications, including skin-associated applications |
| JP2017536106A (ja) * | 2014-06-03 | 2017-12-07 | 韓国科学技術院Ｋｏｒｅａ Ａｄｖａｎｃｅｄ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｓｃｉｅｎｃｅ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ | シグナル伝達経路の活性化状態の分析方法およびこれを用いた個人向け治療剤の選定方法 |
| US10543310B2 (en) | 2011-12-19 | 2020-01-28 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
| US10835163B2 (en) | 2011-04-29 | 2020-11-17 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
| US11177029B2 (en) | 2010-08-13 | 2021-11-16 | Yourbio Health, Inc. | Systems and techniques for monitoring subjects |
| US11202895B2 (en) | 2010-07-26 | 2021-12-21 | Yourbio Health, Inc. | Rapid delivery and/or receiving of fluids |
| US12121353B2 (en) | 2010-11-09 | 2024-10-22 | Yourbio Health, Inc. | Systems and interfaces for blood sampling |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011008990A1 (en) | 2009-07-15 | 2011-01-20 | Prometheus Laboratories Inc. | Drug selection for gastric cancer therapy using antibody-based arrays |
| WO2008036802A2 (en) * | 2006-09-21 | 2008-03-27 | Prometheus Laboratories Inc. | Antibody-based arrays for detecting multiple signal transducers in rare circulating cells |
| BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
| BRPI0813583A2 (pt) | 2007-07-13 | 2014-12-30 | Prometheus Lab Inc | Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo |
| CN103399144B (zh) | 2008-02-25 | 2015-10-28 | 雀巢产品技术援助有限公司 | 用抗体阵列选择乳腺癌治疗药物 |
| WO2012046412A1 (ja) * | 2010-10-07 | 2012-04-12 | パナソニック株式会社 | プラズモンセンサ |
| US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
| WO2013033623A1 (en) | 2011-09-02 | 2013-03-07 | Nestec S.A. | Profiling of signal pathway proteins to determine therapeutic efficacy |
| EP2573565A1 (en) | 2011-09-23 | 2013-03-27 | Gerhard Matthias Kresbach | Immune detection method for common epitopes of two or more analytes in samples of complex compositions, device, and kit for enabling said immune detection method |
| EP3892997A1 (en) * | 2013-01-10 | 2021-10-13 | Emory University | Systems, methods and computer readable storage media for analyzing a sample |
| JP2016148655A (ja) * | 2015-02-05 | 2016-08-18 | 日東電工株式会社 | 計測装置 |
| CN109477084A (zh) * | 2016-07-19 | 2019-03-15 | 国立研究开发法人农业·食品产业技术综合研究机构 | 使用等离子体在植物细胞内导入物质的方法 |
| US10520514B2 (en) * | 2017-02-01 | 2019-12-31 | Korea Institute Of Science And Technology | Method for monitoring post-translational modification of protein |
| US11391735B2 (en) * | 2017-09-06 | 2022-07-19 | AimPlex Biosciences, Inc. | Methods for improving the dynamic range of biological assays |
| KR102342302B1 (ko) * | 2018-09-28 | 2021-12-24 | 주식회사 스몰머신즈 | 정량 분석용 단백질 칩 |
| CN110609078B (zh) * | 2019-09-20 | 2022-03-11 | 南京谱利健生物技术有限公司 | 一种检测蛋白磷酸化和乙酰氨基葡萄糖化关联作用的方法 |
| CN114112305B (zh) * | 2021-12-06 | 2024-02-06 | 西南石油大学 | 一种内外流夹击的柔性立管流固耦合效应测试装置及方法 |
| CN113970644B (zh) * | 2021-12-24 | 2022-05-27 | 天德瑞(北京)生物科技有限公司 | 基于hrp标记蛋白的工作浓度检测方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001092870A2 (de) * | 2000-06-02 | 2001-12-06 | Zeptosens Ag | Kit und verfahren zur multianalytbestimmung |
| WO2002023199A2 (en) * | 2000-09-14 | 2002-03-21 | Reverse Proteomics Research Institute Co., Ltd. | Method, system, apparatus and device for discovering and preparing chemical compounds |
| WO2004009639A1 (ja) * | 2002-07-18 | 2004-01-29 | Cellfree Sciences Co., Ltd. | 単鎖抗体およびその利用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL317379A1 (en) * | 1994-05-27 | 1997-04-01 | Ciba Geigy Ag | Supercritically excited luminescence detecting process |
| EP1890130A3 (en) * | 1995-05-12 | 2008-02-27 | Novartis AG | Sensor platform for the parallel detection of a plurality of analytes using evanescently excited luminescenes |
| DE19628928A1 (de) * | 1996-07-18 | 1998-01-22 | Basf Ag | Feste Träger für analytische Meßverfahren, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung |
| WO1998009156A1 (en) * | 1996-08-29 | 1998-03-05 | Novartis Ag | Optical chemical / biochemical sensor |
| US6087102A (en) * | 1998-01-07 | 2000-07-11 | Clontech Laboratories, Inc. | Polymeric arrays and methods for their use in binding assays |
| AU735887B2 (en) * | 1998-01-09 | 2001-07-19 | Phylogica Limited | Peptide detection method |
| US6197599B1 (en) * | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
| EP1112262B1 (en) * | 1998-09-09 | 2004-08-04 | Inflazyme Pharmaceuticals Ltd. | Substituted gamma-phenyl-delta-lactones and analogs thereof and uses related thereto |
| US20030027214A1 (en) * | 1999-02-17 | 2003-02-06 | Kamb Carl Alexander | Methods for substrate-ligand interaction screening |
| US6972198B2 (en) * | 1999-02-26 | 2005-12-06 | Cyclacel, Ltd. | Methods and compositions using protein binding partners |
| GB0007088D0 (en) * | 2000-03-23 | 2000-05-17 | Torsana A S | Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates |
| US7175811B2 (en) * | 2000-04-28 | 2007-02-13 | Edgelight Biosciences | Micro-array evanescent wave fluorescence detection device |
| EP1315968B1 (de) * | 2000-09-05 | 2008-02-13 | Bayer Technology Services GmbH | Verfahren zur abscheidung von mono- und mehrfachschichten von organophosphor- und -phosphonsäuren und deren salzen sowie deren verwendung |
| US7070740B1 (en) * | 2000-09-28 | 2006-07-04 | Beckman Coulter, Inc. | Method and apparatus for processing biomolecule arrays |
| US7332286B2 (en) * | 2001-02-02 | 2008-02-19 | University Of Pennsylvania | Peptide or protein microassay method and apparatus |
| US7465568B2 (en) * | 2002-04-26 | 2008-12-16 | Bristol-Myers Squibb Company | Essential fungal polynucleotides, polypeptides, and methods of use |
| ATE520027T1 (de) * | 2002-09-03 | 2011-08-15 | Bayer Technology Services Gmbh | Analytische plattform und nachweisverfahren mit gegebenenfalls nach fraktionierung in einer probe nachzuweisenden analyten als immobilisierten spezifischen bindungspartnern |
| US6956651B2 (en) * | 2002-09-07 | 2005-10-18 | Hilary S. Lackritz | Bioanalysis systems including optical integrated circuit |
-
2004
- 2004-03-03 US US10/598,418 patent/US20080020409A1/en not_active Abandoned
- 2004-03-03 CN CNA2004800422474A patent/CN1954213A/zh active Pending
- 2004-03-03 AU AU2004318038A patent/AU2004318038A1/en not_active Abandoned
- 2004-03-03 EP EP04716582A patent/EP1730530A1/en not_active Withdrawn
- 2004-03-03 JP JP2007501122A patent/JP2007526460A/ja active Pending
- 2004-03-03 WO PCT/EP2004/002127 patent/WO2005095965A1/en not_active Ceased
- 2004-03-03 CA CA002559803A patent/CA2559803A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001092870A2 (de) * | 2000-06-02 | 2001-12-06 | Zeptosens Ag | Kit und verfahren zur multianalytbestimmung |
| WO2002023199A2 (en) * | 2000-09-14 | 2002-03-21 | Reverse Proteomics Research Institute Co., Ltd. | Method, system, apparatus and device for discovering and preparing chemical compounds |
| WO2004009639A1 (ja) * | 2002-07-18 | 2004-01-29 | Cellfree Sciences Co., Ltd. | 単鎖抗体およびその利用 |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10799166B2 (en) | 2009-03-02 | 2020-10-13 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving fluids |
| US9730624B2 (en) | 2009-03-02 | 2017-08-15 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving fluids |
| US9775551B2 (en) | 2009-03-02 | 2017-10-03 | Seventh Sense Biosystems, Inc. | Devices and techniques associated with diagnostics, therapies, and other applications, including skin-associated applications |
| US12076518B2 (en) | 2010-07-26 | 2024-09-03 | Yourbio Health, Inc. | Rapid delivery and/or receiving of fluids |
| US11202895B2 (en) | 2010-07-26 | 2021-12-21 | Yourbio Health, Inc. | Rapid delivery and/or receiving of fluids |
| US11177029B2 (en) | 2010-08-13 | 2021-11-16 | Yourbio Health, Inc. | Systems and techniques for monitoring subjects |
| US12310728B2 (en) | 2010-11-09 | 2025-05-27 | Yourbio Health, Inc. | Systems and interfaces for blood sampling |
| US12121353B2 (en) | 2010-11-09 | 2024-10-22 | Yourbio Health, Inc. | Systems and interfaces for blood sampling |
| US10835163B2 (en) | 2011-04-29 | 2020-11-17 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
| US10188335B2 (en) | 2011-04-29 | 2019-01-29 | Seventh Sense Biosystems, Inc. | Plasma or serum production and removal of fluids under reduced pressure |
| US11253179B2 (en) | 2011-04-29 | 2022-02-22 | Yourbio Health, Inc. | Systems and methods for collection and/or manipulation of blood spots or other bodily fluids |
| JP2014516644A (ja) * | 2011-04-29 | 2014-07-17 | セブンス センス バイオシステムズ，インコーポレーテッド | 血斑または他の体液の収集および／または操作のためのデバイスおよび方法 |
| US10543310B2 (en) | 2011-12-19 | 2020-01-28 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
| JP2017536106A (ja) * | 2014-06-03 | 2017-12-07 | 韓国科学技術院Ｋｏｒｅａ Ａｄｖａｎｃｅｄ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｓｃｉｅｎｃｅ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ | シグナル伝達経路の活性化状態の分析方法およびこれを用いた個人向け治療剤の選定方法 |
| JP2020156490A (ja) * | 2014-06-03 | 2020-10-01 | 韓国科学技術院Ｋｏｒｅａ Ａｄｖａｎｃｅｄ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｓｃｉｅｎｃｅ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ | シグナル伝達経路の活性化状態の分析方法およびこれを用いた個人向け治療剤の選定方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1730530A1 (en) | 2006-12-13 |
| CN1954213A (zh) | 2007-04-25 |
| AU2004318038A1 (en) | 2005-10-13 |
| US20080020409A1 (en) | 2008-01-24 |
| WO2005095965A1 (en) | 2005-10-13 |
| CA2559803A1 (en) | 2005-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007526460A (ja) | 細胞集団のタンパク質発現プロファイルの作成のための分析用プラットフォームおよび方法 | |
| AU2013207599B2 (en) | Process for determining one or more analytes in samples of biological origin having complex composition, and use thereof | |
| JP2005537487A (ja) | 試料中において任意には分画された後の試料中において、固定化特異的結合パートナーとして測定される分析対象物を用いる分析プラットフォーム及び検出法 | |
| JP2007526460A5 (enExample) | ||
| US7175811B2 (en) | Micro-array evanescent wave fluorescence detection device | |
| JP2004510130A5 (enExample) | ||
| JP2003507705A (ja) | 複数の分析物を測定するためのデバイス及び方法 | |
| JP2005537486A (ja) | 分析対象物が試料中で固定化された特異的結合パートナーとして測定される分析プラットフォーム及び検出法 | |
| EP1512012B1 (en) | Biomolecular kinetics method using a flow-through microarray | |
| US7563587B2 (en) | Method and kit for cell analyte assay | |
| US9823241B2 (en) | Processing of a sample fluid with target components | |
| ES2369494T3 (es) | Plataforma analítica y procedimiento de detección con analitos a detectar en una muestra eventualmente después del fraccionamiento como asociados de unión específicos inmovilizados. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091027 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100126 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100202 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100301 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100308 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100329 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101005 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20110105 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110920 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120228 |